HOME >> MEDICINE >> NEWS
Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia

CHICAGO - An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center.

"Patients taking dasatinib achieve complete cytogenetic response - absence of the mutated protein that drives this disease - more rapidly than we've observed historically using the current front-line therapy. Side effects are very manageable," says Ehab L. Atallah, M.D., lead author of the study and a fellow in M. D. Anderson's Department of Leukemia. Atallah presented study results at the annual meeting of the American Society of Clinical Oncology in Chicago Saturday June 2nd, 2007. The clinical trial remains in progress with 35 patients enrolled.

Dasatinib, known commercially as Sprycel and produced by Bristol-Myers Squibb, was approved by the U.S. Food and Drug Administration a year ago for use by patients whose disease is unresponsive to or becomes resistant to the front-line therapy imatinib. Both drugs bind to and block a genetically flawed protein known as BCR-ABL, which causes the disease. Atallah explains that dasatinib binds to both forms BCR-ABL while imatinib blocks only one.

"Our hypothesis is that treating with dasatinib first will produce an earlier response, which may translate to a better overall survival," Atallah says. "We haven't proved that here, but these early results are encouraging."

Atallah and colleagues evaluated 35 patients who enrolled in the clinical trial between November 2005 and December 2006. Patients receive either 100 mg of dasatinib once daily or 50 mg twice daily.

Thirty four patients had been on the clinical trial for at least three months when Atallah and lead researcher Jorge Cortes, M.D., professor in the Department of Leukemia, evaluated their data. They found that 77 percent of pati
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
2-Jun-2007


Page: 1 2

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. Most seniors now have drug coverage, U-M study shows
3. Wireless technology shows promise in diagnosing pediatric intestinal disease
4. Study shows radiofrequency ablation highly effective in treating kidney tumors
5. Method shows promise for early detection of pancreatic cancer
6. Organic farming can feed the world, U-M study shows
7. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. New drug shows promise in treatment of advanced thyroid cancer
10. Study shows Diachrome improves blood sugar control in people with type 2 diabetes
11. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... PHOENIX (PRWEB) , ... September 01, 2020 , ... ... of care for children with Pediatric Feeding Disorder (PFD), is pleased to announce that ... be a stand-alone diagnostic code (R code) in the next edition of the U.S. ...
(Date:8/31/2020)... ... 31, 2020 , ... Cardiothoracic surgeons at Allegheny General Hospital ... Mellon University (CMU) to develop a new heart monitoring device designed to serve ... , The AGH/CMU team was recently awarded a “Trailblazer” grant from the National ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... 1,400 N95 face masks to medical first responders across the United States. Since ... donations of personal protective equipment (PPE) medical centers , hospitals , ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... higher-learning opportunities through high-quality, career-relevant, and affordable online education – is proud to ... , Among the first of its kind in the nation, the 60-credit ...
(Date:8/31/2020)... ... 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis , At ... a state of panic, experiencing deep anxiety, immense stress, and right now are needing serious ... when most people on the planet are experiencing a great degree of emotional discomfort, be ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... September 03, 2020 , ... In response ... return to schools and classrooms across the United States, IntraLogic Solutions , ... product line. TEMPE is a non-contact, wall-mounted scanning thermometer that rapidly checks body ...
(Date:9/1/2020)... ... September 01, 2020 , ... Mara C. Weinstein Velez, ... at the University of Rochester Medical Center, in Upstate New York. She completed ... with clinical faculty from the Harvard and Yale Departments of Dermatology and is ...
(Date:8/31/2020)... ... August 31, 2020 , ... Welltech1, the first Israeli ... have invested $400,000 in PopBase, one of two start-ups that beat 152 companies ... Institute (GWI). , The competition was part of the GWI’s The Wellness ...
Breaking Medicine Technology:
Cached News: